HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy

Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes

“…Meanwhile, triple negative subtype commonly found in <50 years old, similar to studies in Thai and Iran (Chuthapisith et al, 2012;Kadivar et al, 2012;Najafi et al, 2013). These results suggested that luminal A subtype cancers were associated with favorable clinicopathological factors while Her-2 positive and triple negative subtypes were associated with poor outcomes (Carey et al, 2006;Bosch et al, 2010;Su et al, 2011;Jia et al, 2014).…”

“…Study in china found luminal B cancer had smaller tumor size than luminal A cancer. However, luminal B and luminal A subtypes showed similar rates of lymph node metastasis and age (Jia et al, 2014). Her-2+ subtype in this study was mostly occured in large size tumor, positive lymph node metastasis and poor grade variable.…”

“…The triple negative/basal-like subtype was significantly correllated with familial breast cancers (Su et al, 2011). Another research in China found that luminal A cancers have the best prognosis, whereas Her-2+ cancers have the poorest (Jia et al, 2014). Breast cancer study in Egypt found the highest frequency was luminal A subtype, followed by triple negative, Her-2+, and luminal B cancers.…”

“…Luminal A subtype cancers also had lower recurency rate (27.8%) and higher survival rate (median survival rate: 2.2 years) in compare to non luminal cancers (Eroles et al, 2012;Guarneri et al, 2009). A study in Chinese cancer women found that luminal A subtype had the highest locoregional relaps -free survival (93.2%), distant metastasis-free survival (91.5%) and disease free survival rates (87.5%) at 5 years, while Her-2+ subtypes showed the highest rate reccurence (27.5%) and locoregional recurrence (11.4%) (Jia et al, 2014).…”

Value of Porous Titanium Alloy Plates for Chest Wall Reconstruction after Resection of Chest Wall Tumors

“…The optimal therapy for chest wall tumors is surgical resection, in which local resection can be performed on benign or malignant tumors (Afsharfard et al, 2013;Alipour et al, 2014;Fouladi et al, 2014;Hu et al, 2013;Sedighi et al, 2013;Talaiezadeh et al, 2013;Zhu et al, 2013;Hu et al, 2014;Jia et al, 2014;Ozkan-Gurdal et al, 2014). However, the resection range should be properly enlarged to such tumors as desmoids, chondroma and osteoclastoma, or be resolved as in malignant tumors, though with benign pathological examinations (Errani et al, 2010;Nieuwenhuis et al, 2011).…”